Park Ha Biological Technology Co., Ltd. Announces Pricing of $2.0 Million Registered Direct Offering

Park Ha Biological Technology (NASDAQ: BYAH) priced a registered direct offering of up to 1,133,332 Class A shares and pre-funded warrants for 200,000 shares at $1.50 per security, for expected gross proceeds of about $2.0 million.

Rhea-AI Summary

Park Ha Biological Technology (NASDAQ: BYAH) priced a registered direct offering of up to 1,133,332 Class A shares and pre-funded warrants for 200,000 shares at $1.50 per security, for expected gross proceeds of about $2.0 million.

The offering is expected to close around June 15, 2026, with D. Boral Capital as sole placement agent. Net proceeds are earmarked for general corporate and working capital purposes under an effective Form F-3 shelf registration.

Positive

• Approximately $2.0 million in expected gross proceeds from the registered direct offering
• Up to 1,133,332 new shares plus 200,000 warrant shares placed with investors at a fixed price
• Net proceeds designated for general corporate and working capital purposes
• Use of an effective Form F-3 shelf registration may support future capital access

Negative

• Issuance of up to 1,333,332 additional shares including warrant shares may dilute existing shareholders
• Offering priced at a fixed $1.50 per share or pre-funded warrant, limiting upside if demand strengthens before closing

Argus Jun 12 session

+40.00% close to close Open Argus

Details

News Market Reaction – BYAH

In the Jun 12 session, BYAH gained 40.00%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +40.0% in the session following this news. A strong positive reaction aligns with h...

Analysis

The stock surged +40.0% in the session following this news. A strong positive reaction aligns with heavy liquidity and a very depressed starting point, as BYAH traded far below its 200-day MA and 52-week high. Historically, offerings around BYAH averaged moves near -23.84%, so the +88.58% move around this registered direct deal marked a sharp break from prior dilution-driven selloffs. With an active F‑3 shelf enabling additional issuance, repeated equity raises remained a key overhang that could have limited how long such a spike persisted.

Key Figures

Registered direct proceeds: $2.0M Shares offered: 1,133,332 shares Pre-funded warrants: 200,000 shares +5 more

Registered direct proceeds

$2.0M

Gross proceeds from June 2026 registered direct offering

Shares offered

1,133,332 shares

Class A ordinary shares in June 2026 offering

Pre-funded warrants

200,000 shares

Warrant shares underlying pre-funded warrants in offering

Offering price

$1.50

Combined purchase price per share or pre-funded warrant

Shelf size

$300,000,000

Maximum aggregate amount under Form F-3 shelf registration

Prior units offered

21,875,000 units

January 2026 follow-on public offering

Prior offering price

$0.112 per unit

Pricing of January 2026 follow-on units

Prior gross proceeds

US$2.45M

Gross proceeds from January 2026 follow-on offering

Previous Offering Reports

2 past events · Latest: Jan 28

Same Type 2 events

1. Jan 28

   Offering closing

   24h Move

   -23.6%

   Closed US$2.45M follow-on unit offering with attached warrants.

2. Jan 27

   Offering pricing

   24h Move

   -24.1%

   Priced US$2.45M best-efforts follow-on unit offering at US$0.112.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, pre-funded warrants, shelf registration statement, form f-3, +1 more

5 terms

registered direct offering financial

"entered into a securities purchase agreement ... in a registered direct offering (the “Offering”)"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

pre-funded warrants financial

"and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 200,000 Class A ordinary shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"pursuant to an effective “shelf” registration statement on Form F-3 (File No. 333-295090)"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form f-3 regulatory

"registration statement on Form F-3 (File No. 333-295090) previously filed with the U.S. SEC"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

prospectus supplement regulatory

"A prospectus supplement and accompanying prospectus relating to the offering will be filed"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Wuxi, China, June 12, 2026 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd., (NASDAQ: BYAH) an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), today announced that it has entered into a securities purchase agreement with several investors for the sales of the Company’s securities in a registered direct offering (the “Offering”) consisting of up to 1,133,332 of the Company’s Class A ordinary shares, par value $0.001 each (the “Shares”), and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 200,000 Class A ordinary shares (the “Warrant Shares”), at a combined purchase price of $1.50 per Share and Pre-Funded Warrant. The gross proceeds to the Company from this Offering are expected to be approximately $2.0 million.

The Offering is expected to close on or about June 15, 2026, subject to customary closing conditions.

D. Boral Capital LLC is acting as the sole placement agent for the offering.

The Company intends to use the net proceeds from this Offering for general corporate and working capital purposes.

The securities in the Offering are being offered pursuant to an effective “shelf” registration statement on Form F-3 (File No. 333-295090) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective on June 8, 2026 under the Securities Act of 1933, as amended (the “Securities Act”). A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About the Company

Established in 2016, Park Ha Biological Technology Co., Ltd. is primarily engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions under the proprietary brand “Park Ha”, with a commitment to providing cost-effective solutions to skin problems and improving the confidence of women in need of skin treatment. As of October 31, 2025, the Company has five directly operated stores and 22 franchisees in China. As part of its value-added service for the products, the Company offers “light beauty experience”, a quick complimentary after-sales beauty service performed in the directly operated stores and franchise stores. For more information, please visit the Company’s website: http://ir.parkha.cn/. 

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may”, “will”, “expect”, “anticipate”, “aim”, “estimate”, “intend”, “plan”, “believe”, “is/are likely to”, “potential”, “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

D. Boral Capital LLC
590 Madison Avenue, 39th Floor
New York, NY 10022
Main Phone: +1 (212) 970-5150
www.dboralcapital.com
info@dboralcapital.com

Park Ha Biological Technology Co., Ltd.
901, Building C
Phase 2, Wuxi International Life Science Innovation Campus
196 Jinghui East Road
Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000
http://ir.parkha.cn/
ir_parkha@163.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key details of Park Ha Biological (NASDAQ: BYAH) $2.0 million registered direct offering announced June 12, 2026?

Park Ha Biological priced a registered direct offering expected to raise about $2.0 million in gross proceeds. According to the company, it will sell up to 1,133,332 Class A shares and pre-funded warrants for 200,000 shares at $1.50 per security.

How many new BYAH shares and pre-funded warrants are included in Park Ha Biological’s June 2026 offering?

The transaction includes up to 1,133,332 Class A ordinary shares and pre-funded warrants for 200,000 additional shares. According to the company, each share or pre-funded warrant is offered at a combined purchase price of $1.50 in the registered direct offering.

When is the closing date for Park Ha Biological’s registered direct offering of BYAH shares?

The offering is expected to close on or about June 15, 2026, subject to customary conditions. According to the company, D. Boral Capital LLC is acting as the sole placement agent for this registered direct equity financing.

What will Park Ha Biological use the $2.0 million BYAH offering proceeds for?

Net proceeds are planned for general corporate and working capital purposes. According to the company, funds from the approximately $2.0 million gross registered direct offering will support ongoing operations rather than any specified acquisition or debt repayment.

How might Park Ha Biological’s June 2026 registered direct offering affect existing BYAH shareholders?

The offering may dilute existing shareholders by increasing the number of outstanding shares. According to the company, up to 1,133,332 new shares and 200,000 warrant shares could be issued, potentially reducing existing investors’ ownership percentage once the transaction closes.

Under what SEC registration is Park Ha Biological conducting its BYAH registered direct offering?

The securities are being offered under an effective shelf registration statement on Form F-3, File No. 333-295090. According to the company, this registration was declared effective on June 8, 2026, and a prospectus supplement will be filed with the SEC.